Jul 19, 2022 / 12:00PM GMT
Operator
Good morning, ladies and gentlemen, and welcome to Incyte's conference call and webcast to discuss Opzelura in vitiligo approval call. (Operator Instructions)
As a reminder, today's conference is being recorded. It is now my pleasure to introduce your host, Ms. Christine Chiou, Head of Investor Relations. Thank you. Please go ahead.
Christine Chiou - Incyte Corporation - Head of IR
Thank you, Donna. Good morning, and welcome to Incyte's conference call and webcast to discuss the FDA approval of Opzelura for the treatment of nonsegmental vitiligo, which was announced Monday, July 18.
Speaking on the call today are -- from Incyte are Herve; Jim Lee, our Head of Development in Inflammation and Autoimmunity; and Todd Edwards, our Dermatology Business Unit Head. Barry, Steven and Christiana will also participate in the Q&A session.
I also have the pleasure of introducing Dr. Seemal Desai, a Board Certified Dermatologist in private and academic practice in Dallas, Texas, and clinical assistant professor in the Department of Dermatology
Incyte Corp to Discuss Opzelura In Vitiligo FDA Approval Call Transcript
Jan 23, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers